Entrectinib

Category: Cancer



Entrectinib Overview

Entrectinib (INN,[2] trade name Rozlytrek previously known as RXDX-101 and NMS-E628) is an anti-cancer drug used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It was approved in the United States on 15 August 2019.[3][4][5] It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK)....

Read more Entrectinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Entrectinib

Recent Entrectinib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Entrectinib
  • Capsule: 100mg, 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Entrectinib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 14 December 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA